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Abstract: 
Background:  
Frailty is common in patients with chronic heart failure (CHF) and is associated with adverse 
outcome, but few data exist.  
 
Objectives:  
To report the prevalence of frailty and agreement amongst 3 frailty assessment tools and 3 
screening tools in CHF patients.   
 
Methods: 
We used the following frailty screening tools: the clinical frailty scale (CFS); the Derby 
frailty index (DFI); and the acute frailty network (AFN) frailty criteria. We used the 
following frailty assessment tools: the Fried criteria; the Edmonton frailty score (EFS); and 
the deficit index (DI).  
 
Results: 
467 consecutive ambulatory CHF patients (67% male, median age 76 (interquartile range 
(IQR):69-82 years), median NTproBNP 1156 (IQR:469-2463) ng/L) and 87 controls (79% 
male, median age 73 (IQR:69-77 years) were studied. The prevalence of frailty using the 
different tools was higher in CHF patients than in controls (30-52% vs 2-15%, respectively).   
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Frail patients tended to be older, have worse symptoms, higher NTproBNP and more co-
morbidities. Of the screening tools, CFS had the strongest correlation and agreement with the 
assessment tools (correlation coefficient: 0.86-0.89, kappa coefficient: 0.65-0.72, depending 
on the frailty assessment tools, all p<0.001). CFS had the highest sensitivity (87%) and 
specificity (89%) amongst screening tools and the lowest misclassification rate (12%) 
amongst all 6 frailty tools in identifying frailty according to the standard combined frailty 
index. 
 
Conclusion: 
Frailty is common in CHF patients and is associated with increasing age, co-morbidities and 
severity of HF. CFS is a simple screening tool which identifies a similar group as more 
lengthy assessment tools.  
(250 words) 
 
Key words: heart failure, frailty screening, assessment 
 
Abbreviations: CHF = chronic heart failure, LVEF = left ventricular ejection fraction, 
NTproBNP = N-terminal pro B-type natriuretic peptide, HeFREF = heart failure with reduced 
ejection fraction, HeFNEF = heart failure with normal ejection fraction, DFI = Derby frailty 
index, AFN = the acute frailty network criteria, CFS = clinical frailty scale, EFS = Edmonton 
frailty scale, DI = the deficit index 
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Introduction: 
Frailty is common in patients with chronic heart failure (CHF) and is associated with 
increased risk of death and hospitalisations.
1,2,3 
However, there is no standard method for 
evaluating frailty in patients with CHF.   
 
Tools to evaluate frailty stem from two basic concepts of frailty – physical frailty and multi-
dimensional frailty.  
 The first was proposed by Fried and colleagues, who defined frailty as a physical 
syndrome using five criteria (Fried criteria): weak grip strength, unintentional weight 
loss, exhaustion, slow walking speed and low physical activity.
4
  
 The second concept was proposed by Rockwood et al who defined frailty as a state of 
vulnerability due to accumulation of health deficits. Frailty is measured by a deficit 
index which quantifies the cumulative burden of deficits. 
5,6 
 The Edmonton frailty 
scale (EFS) is a simplified frailty assessment tool based on the concept of multi-
dimensional frailty which has been shown to have good construct validity and 
reliability.
7
 
 
 
Despite their prognostic value and wide-spread use in research, the Fried criteria and the 
deficit index are not routinely used in clinical practice as they are time consuming to perform. 
Simple screening tools
8
 
9
 
10
 have been developed, but it is not clear whether they identify the 
same patients as the more comprehensive assessment tools. 
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Very few studies have simultaneously evaluated different tools to quantify frailty in the same 
cohort of patients with CHF.
11
 To the best of our knowledge, no study has ever compared the 
efficacy of frailty screening tools versus assessment tools in patients with CHF.  We therefore 
evaluated frailty in a cohort of patients with CHF using 3 commonly used frailty screening 
tools and 3 commonly used frailty assessment tools. We compared the efficacy of simple 
screening tools versus more comprehensive assessment tools in detecting frailty in patients 
with CHF.  
 
Methods 
Study population 
Consecutive ambulatory patients with CHF attending a community heart failure clinic were 
enrolled between September 2016 and March 2017. All patients had a pre-existing (>1 year) 
clinical diagnosis of CHF confirmed by either evidence of left ventricular systolic 
dysfunction on echocardiography (left ventricular ejection fraction (LVEF) <40% or at least 
moderate left ventricular systolic dysfunction by visual inspection if LVEF was not 
calculated), defined as heart failure with reduced ejection fraction, HeFREF; or normal left 
ventricular systolic function (LVEF >40% or better than, or equal to, mild-moderate left 
ventricular systolic dysfunction by visual inspection) and N-terminal pro-B-type natriuretic 
peptide (NTproBNP) >400 ng/L, defined as heart failure with normal ejection fraction, 
HeFNEF.
12
  
 
All patients had already been initiated on guideline-indicated treatment for heart failure and 
were regularly followed up.   
Dr. Sze – Screening 11.8.2018 
  
 
Subjects who had previously consented to take part in research were recruited as controls. 
Control subjects were older than 65 years of age, with no previous or current symptoms or 
signs of HF and with normal left ventricular systolic function on echocardiography who also 
had risk factors for development of HF, including coronary artery disease, diabetes mellitus 
or hypertension.   
 
During the visit, all patients had a full medical history, physical examination, blood tests (full 
blood count, urea and electrolytes and NTproBNP), an electrocardiogram and a consultation 
with a HF specialist.  
 
Frailty screening and assessment  
 
All patients and controls were screened and assessed by the same researcher (SS) for frailty 
(Appendix 1a) 
 
The screening tools used were: 
1) The Derby frailty index (DFI; scores as frail vs non-frail) 
DFI is a quick pragmatic frailty identification tool initially developed in 2013.
9
 A 
patient is classified as frail if one of the following criteria is met: 1) ≥65 years old and 
a care home resident; 2) ≥75 years old with confusion, falls or reduced mobility; 3) ≥ 
85 years old with >4 co-morbidities.  
2) The acute frailty network criteria (AFN; scores as frail vs non-frail)  
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AFN defines frailty as present in (a) people aged ≥85 years or (b) people aged ≥65 
years with one or more of the following presenting features: cognitive impairment; 
resident in a care home; history of fragility fractures; Parkinson’s disease; recurrent 
falls.
10
 
 
3) The clinical frailty scale (CFS; measures between 1 (very fit) and 9 (terminally ill)) 
Subjects are scored according to their functional capacity, level of dependence and 
co-morbidities. For example, a patient with uncontrolled symptoms who is not frankly 
dependent is classified as vulnerable and scores 4 on the CFS; while an individual 
with limited dependence on others for instrumental activities of daily living including 
finances, transportation, heavy housework and medications will be classified as 
mildly frail and scores 5 on the CFS.  Subjects with a CFS >4 are classified as frail.
8
 
 
The assessment tools used were: 
1) Fried frailty phenotype (measures between 0 (normal) and 5 (very frail)): 
The Fried Frailty phenotype
4
 is commonly used to validate other frailty criteria. 
Frailty is considered as a clinical syndrome based on five criteria: unintentional 
weight loss (≥10 lbs [≥4.5 kg] in the past year); self-reported exhaustion; weakness 
(low grip strength); slow walking speed (time to walk 5 meters ≥ 6-7 seconds 
depending on sex and height); and low physical activity (low weekly total energy 
expenditure assessed using the short version of the Minnesota Leisure Time Activity 
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questionnaire
13
.) (Appendix 1b) Subjects with ≥ 3 points are classified as frail and 
those with 1-2 points and 0 points are classified as pre-frail and non-frail respectively.
 
   
 
2) Edmonton frailty scale (EFS; measures between 0-17)  
EFS is a multi-dimensional frailty assessment tool which includes general health 
status, functional independence, social support, cognition, medication use, nutrition, 
continence and mood.
7 
EFS has been validated against the comprehensive geriatric 
assessment (CGA),
14
 a multi-dimensional, multidisciplinary diagnostic process used 
to determine medical, functional and psychosocial problems in elderly patients.
7
 
Subjects with EFS 0-5 are classified as non-frail, those with EFS 6-7, 8-9, 10-11 and 
12-17 are classified as vulnerable, mildly, moderately and severely frail respectively. 
Subjects with EFS ≥ 8 are classified as frail.  (Appendix 1c) 
 
3) The Deficit Index (DI; measures between 0.03-0.72) 
Mitnitski and Rockwood consider frailty as a clinical state as a result of accumulation 
of deficits (symptoms, signs, co-morbidities and disabilities).
15
 These deficits are 
combined in a frailty index score to reflect the proportion of potential deficits present 
in a person.
  
We selected 32 deficits according to previously published criteria
6
 to 
construct the deficit index.  The first 14 items of the DI were related to activities of 
daily living which were collected by direct questioning of participants. The remaining 
items were based on information from patient’s medical records or physical tests 
during the visit.  If a subject exhibited 5 out of the 32 possible deficits, the frailty 
index for that patient would be 5/32 or 0.16. We stratified patients and controls 
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according to terciles of DI; those in the lower tercile were classified as non-frail while 
those in the middle and upper terciles were classified as pre-frail and frail 
respectively.  (Appendix 1d) 
 
Physical Tests: 
a) Handgrip strength (HGS):  
Hand grip strength was obtained with a handgrip dynamometer (Es-100 Ekj107, 
Evernew, Japan). The subject was seated with forearm resting on the arm of a chair 
and instructed to hold the dynamometer upright and squeeze as hard as possible. 
Three trials in the right hand followed by three trials in the left hand were recorded 
and the highest reading of the 6 was taken as the final reading.   
 
b) Gait analysis 
1) Timed get up and go test: 
The area for the timed get up and go test was set up by measuring 3 meters from the 
front legs of a straight-backed armchair. The subject was instructed to: "Sit with your 
back against the chair and your arms on the arm rests. On the word `go,' stand upright, 
then walk at your normal pace to the line on the floor, turn around, return to the chair, 
and sit down." The time required to complete the test was time from the word `go' to 
time when the subject returned to the starting position. Subjects who took more than 
10 seconds to complete the test were classified as frail. (Appendix 1c) 
 
2)  Five metre walk test:  
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The subject was instructed to walk at a normal pace for 5 meters according to their 
ability. The time required to complete the test was time from the word `go' to time 
when the subject reached the 5-meter-point. Subjects who took more than 6-7 seconds 
(depending on sex and height) to complete the test were classified as frail. (Appendix 
1b) 
 
Co-morbidities 
Co-morbidities were measured using the Charlson co-morbidity index/score.
16
 Hypertension 
was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg or a 
previous clinical diagnosis.
17
 Current haemoglobin (Hb) levels were used to define anaemia 
(Hb <13.0 g/dL in men and <12.0 g/dL in women).
18
  Diabetes mellitus was defined 
according to the guideline from Diabetes UK.
19
 Patients consented to the use of electronic 
medical records to identify previous clinical history of myocardial infarction, peripheral 
vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), 
dementia, rheumatological disease, peptic ulcer, hemiplegia/ paraplegia, liver or renal disease 
or malignancy. 
 
Statistical analysis 
Continuous data are expressed as a median with interquartile range (IQR) (25
th
 to 
75
th
 centiles) and categorical data are expressed as n (%). Independent t tests and Mann-
Whitney U tests were used to compare two continuous variables for normally and non-
normally distributed data. The chi-squared test was used to compare proportions between 
groups.  Pearson’s correlation or Spearman’s correlation coefficients were used to assess the 
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relationships between two variables. Venn diagrams were used to illustrate the relationship 
between screening and assessment tools.  Kappa statistics were used to study the agreement 
between frailty screening tools and assessment tools.  
 
Since there is no gold standard in evaluating frailty in patients with CHF, for each of the 
frailty tools, we used the results of the other 5 tools to produce a single combined frailty 
index which we assumed to be the gold standard frailty tool. This methodology has been 
previously suggested by Pablo et al.
20
 Similarly, for each of the physical tests (timed get up 
and go test, 5 metre walk test and hand grip strength), we used the results of the 5 frailty tools 
which do not include the physical test, to produce a single combined frailty index as the gold 
standard frailty tool.  Subjects were defined as frail if so identified by at least 3 of the 5 tools. 
The sensitivity, specificity and predictive values for each of the individual tools and physical 
tests in identifying frailty according to the combined index were calculated. 
 
To investigate the bias associated with CFS being a subjective frailty screening tool, in 
addition to the principal investigator (SS), a second investigator (JW) also completed the CFS 
for a random sample of 23 patients. Kappa statistics were used to determine the inter-operator 
agreement.   
 
All statistical analyses were performed using SPSS 22 (SPSS INc.,Chicago, IL, USA) and 
The Stata (14
th
 Version, StataCorp, TX, USA) statistical computer package. A two-tailed P-
value of <0.05 was considered significant in all analyses. 
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The study conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent for their 
data to be used for research. 
 
Results 
A total of 467 consecutive patients with CHF and 87 controls was studied. Table 1a shows 
the baseline characteristics of the HF cohort vs controls. The majority of patients and controls 
were male and elderly; 17% of those with CHF were older than 85 years (vs 2% of controls). 
Most of the patients with CHF had HeFREF (62%) with a median NTproBNP of over 
1100ng/L; around one fifth had severe symptoms (NYHA III/IV).  
 
Prevalence of frailty 
The prevalence of frailty varied according to frailty tools used.  It was much more common in 
patients than in controls, regardless of the frailty tool used (HF: 30-52% vs controls: 2-15%).  
(Table 2)  
 
Amongst the frailty assessment tools, the Fried criteria scored the greatest proportion of 
patients as frail (52%) while EFS scored the lowest proportion as frail (30%) (Figure 1). 26% 
(N=119) of patients were classified as frail by all 3 assessment tools. (Central illustration)  
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Amongst the frailty screening tools, DFI scored the greatest proportion of patients as frail 
(48%) while CFS scored the lowest proportion as frail (44%) (Figure 1). 27% (N=128) of 
patients were classified as frail by all 3 screening tools. (Central illustration) 
 
The prevalence of frailty was higher in patients with HeFNEF than HeFREF. (Table 3) The 
prevalence of frailty was higher in patients with atrial fibrillation (AF) than in those in sinus 
rhythm. The prevalence of frailty increased with decreasing BMI and increasing NYHA 
class, age and NTproBNP.  
 
Prevalence of pre-frailty 
The prevalence of pre-frailty varied greatly depending on the assessment tool used. (Table 2) 
According to the EFS, the prevalence of pre-frailty was much higher in patients than controls, 
but according to the Fried criteria, pre-frailty was as common in both groups.   
 
The Fried criteria scored the greatest proportion of patients as pre-frail (32%) while the EFS 
scored the lowest proportion as pre-frail (19%). (Figure 1)   Only 3% (N=13) of patients were 
classified as ‘pre-frail’ by all 3 assessment tools (Appendix 2) 
 
Relationship between frailty and clinical data 
Compared to those who are not frail, frail patients were older, had worse symptoms, higher 
NTproBNP, worse renal function and anaemia. They were more likely to be on diuretics but 
less likely to be on ACE-inhibitors, beta-blockers and mineralocorticoid antagonist; they also 
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had a lower BMI and more co-morbidities: especially dementia, COPD, depression, recurrent 
falls and incontinence. (Table 1b) 
 
Relationship between different frailty tools 
The relationship between the results of the frailty scores is shown in Table 4. Of the 3 frailty 
screening tools, CFS had the strongest correlation with the frailty assessment tools 
(correlation coefficient: 0.86-0.89, depending on the frailty assessment tools, all P<0.001) 
 
Detection of frailty: screening tools vs assessment tools 
Of the screening tools, CFS had the highest and DFI the lowest agreement with the 
assessment tools in distinguishing between frail and non-frail patients. (Table 5) 
 
Frailty tools vs combined index 
Table 6 shows the sensitivity, specificity and misclassification rates of different frailty tools 
(screening vs assessment vs single physical tests) in identifying frailty according to the 
combined index (the presumed gold standard for identifying frailty).  
 
Of the screening tools, CFS had the highest sensitivity (87%) and specificity (89%). DFI had 
the highest false positive rate (16%) and false negative rate (10%). CFS had the lowest 
misclassification rate (12%). 
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Of the assessment tools, the Fried criteria had the highest sensitivity (93%) and EFS had the 
highest specificity (98%). The Fried criteria had the highest false positive rate (14%) and EFS 
has the highest false negative rate (18%).  
 
Of the three single physical tests, timed get up and go test had the highest sensitivity (97%) 
and 5m walk test had the highest specificity (59%). Grip strength had the highest false 
positive rate (25%) and false negative rate (3%). Overall, timed get up and go test had the 
lowest misclassification rate (25%).  
 
Compared to frailty assessments or screening tools, single physical tests have higher overall 
sensitivities but lower specificities and higher misclassification rates.  
 
Inter-operator agreement of CFS: 
There was close agreement between the two operators’ judgements on degree of frailty in a 
random sample of subjects (N=23) using the CFS, with a Kappa coefficient (K) of 0.72 (95% 
CI: 0.51-0.93, p<0.001).  
 
Time needed to complete frailty screening vs assessment: 
Frailty screening on average takes no more than 1 minute to complete, whereas frailty 
assessment on average takes 15 minutes to complete, depending on the mobility of patients.  
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Discussion 
We found that frailty is very common amongst outpatients with CHF, but that the prevalence 
varied from 30 to 52% depending on the assessment tool used. Our findings are similar to 
those from a meta-analysis involving 5522 ambulatory patients with CHF or older adults 
aged 70 to 79 years. Frailty was assessed by several tools including the Fried criteria, 
comprehensive geriatric assessment, the deficit index, frailty staging system, modified frailty 
scale and the Health ABC Short Physical Performance Battery (HABC battery) and Gill 
index.  The prevalence of frailty was between 18 and 54% depending on the population 
studied.
21
 There was substantial variance in prevalence of frailty in the meta-analysis 
probably due to heterogeneity of populations studied. Our results are a more accurate 
reflection of the true prevalence of frailty in patients with CHF as we evaluated frailty using 6 
different scoring tools in the same cohort of patients.   
 
Frailty was more common in patients with HeFNEF than in patients with HeFREF. The 
patients with HeFNEF were older and had a greater burden of non-cardiac co-morbidities, 
themselves associated with reduced functional status and increased risk of hospitalisation.
22,23
 
AF becomes more common with age, and is particularly common in patients with HeFNEF. It 
is itself associated with the development and progression of frailty.
24
 
 
Ours is the first paper to compare simple frailty screening tools with more comprehensive 
assessment tools in patients with CHF. Whilst we found that there was substantial overlap 
between patients identified as frail by each tool, the overlap was not very great. Although we 
found a correlation between frailty screening and assessment tools, the relation was modest 
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for some, suggesting that the tools are measuring differing aspects of a common phenotype, 
and that none is on its own definitive. 
 
The different tools have strengths and weaknesses. The Fried criteria objectively measure 
physical functioning, but other domains, particularly cognition, are not considered. The DI 
covers multiple domains including physical functioning and co-morbidities, and is thus a 
more comprehensive tool than the Fried criteria. The EFS, similar to DI, also examines 
multiple domains including cognition, social support, medication, nutrition and mood; it also 
includes straightforward physical performance measures (timed get up and go test). Frailty 
assessments require significant time to perform (on average 10-15 minutes depending on the 
mobility of patients), which is not ideal in busy clinical settings.  
 
Screening tools are much easier to use. They do not require physical measurements to be 
carried out and can be completed within a minute. Amongst the screening tools, CFS has the 
highest sensitivity and specificity with the lowest misclassification rate. We found that CFS, 
was as effective as lengthy frailty assessments in detecting frailty, and it is therefore 
appealing for use in clinical practice. CFS has a subjective component, but we found inter-
operator agreement to be good.   
 
Worsening results on physical performance measures such as grip strength and walking speed 
predict increasing mortality and risk of institutionalisation.
25,26
 We found that single physical 
tests have higher sensitivities but lower specificities than frailty assessment or screening 
tools, and higher misclassification rates. Further studies will clarify whether single physical 
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measures or simple frailty screening tools have comparable prognostic value to more 
comprehensive frailty assessments.  
 
Study limitations 
Firstly, because this is a single-centre study conducted in the UK with limited sample size, 
external validation of our results from other populations with different healthcare and social 
systems is needed. Our study is, however, the largest study which directly compares several 
commonly used frailty screening and assessment tools in consecutive, unselected, patients 
with CHF. 
 
Secondly, we have only studied 6 of the most commonly used frailty tools in literature. A 
large number of frailty screening and assessment tools has been proposed and identified 
patients at risk of adverse outcome in other clinical scenarios.
27
   
 
Thirdly, this study only focuses on reporting prevalence of frailty by the different tools, but 
we have not evaluated the predictive role of these tools.  
 
Fourthly, we only included patients with a diagnosis of dementia if they had capacity in the 
investigator’s opinion to consent for the study. We are therefore unable to report on frailty in 
patients with dementia so severe as to be considered lacking in capacity. 
 
Conclusion 
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Frailty is common in patients with CHF.  CFS is a short and easy to use frailty screening tool, 
which has comparable effectiveness to lengthy frailty assessments in identifying frailty. CFS 
should therefore be considered when assessing patients with CHF to enable identification of 
at-risk individuals. Further work is required to study the prognostic value of simple screening 
vs assessment tools in patients with CHF. 
 
 
Perspectives: 
Competency in medical knowledge 1: Frailty is common in patients with CHF, with a 
prevalence of 30 -52% depending on the screening or assessment tool used.  
Competency in medical knowledge 2: Frailty is associated with increasing age, co-
morbidities and severity of HF.  
Competency in medical knowledge 3: CFS is a short and easy to use frailty screening tool 
which has comparable effectiveness to lengthy frailty assessments in identifying frailty in 
patients with CHF. CFS should be considered when assessing patients with CHF. 
Translational outlook: Recognition of the high prevalence of frailty in patients with CHF 
should stimulate further research on the prognostic value of simple screening vs assessment 
tools.  
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Table 1a. Baseline characteristics of HF cohort vs controls. 
 Controls 
(N=87) 
HF 
(N=467) 
p Missing 
Demographics 
Age, years 73 
(69-77) 
76 
(69-82) 
0.11 0 
Age≥85 years, Ŷ;%Ϳ 2(2) 81(17) <0.001 0 
Sex (male), n(%) 69(79) 313(67) 0.02 0 
HR (bpm) 61 
(55-70) 
70 
(60-80) 
<0.001 0 
BP systolic (mmHg) 144 
(130-152) 
139  
(126-162) 
0.98 0 
BP diastolic (mmHg) 76  
(70-82) 
75  
(66-83) 
0.40 0 
NYHA, n(%) 
I/II  
III/IV 
 
- 
- 
 
364 (78) 
103 (22) 
 0 
HF phenotype, n(%) 
HeFREF 
HeFNEF 
NA  
291 (62) 
176 (38) 
 0 
LVEF (%) 58 
(53-64) 
45 
(35-54) 
<0.001 160 
LV systolic impairment, n(%) 
None-mild 
Moderate-severe 
 
87 (100) 
0 
 
252 (54) 
215 (46) 
<0.001 0 
Height (m) 1.71  
(1.63-1.75) 
1.68  
(1.61-1.75) 
0.20 0 
Weight (kg) 81  
(73-92) 
83  
(69-99) 
0.22 0 
BMI (kg/m
2
) 27.8 
 (25.2-30.8) 
29.0 
(25.0-33.2) 
0.08 0 
BMI categories (kg/m
2
) 
<24.9 
25.0-29.9 
≥30.0 
 
18 (21) 
42 (48) 
27 (31) 
 
111 (24) 
158 (34) 
198 (42) 
0.03 0 
Comorbidities 
Charlson score 6  
(4-7) 
8  
(6-10) 
<0.001 0 
MI, n(%) 27 (31) 198 (42) 0.05 0 
PVD, n(%) 16 (18) 72 (15) 0.49 0 
HTN, n(%) 61 (70) 313 (67) 0.57 0 
CVA/TIA, n(%) 5 (6) 71 (15) 0.02 0 
Diabetes, n (%) 35 (40) 163 (35) 0.24 0 
Dementia, n(%) 1 (1) 48 (10) 0.006 0 
COPD, n(%) 16 (18) 140 (30) 0.03 0 
Depression, n(%) 9 (10) 93 (20) 0.03 0 
Anaemia, n(%) 22 (25) 218 (47) <0.001 0 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recurrent falls, n(%) 5 (6) 173 (37) <0.001 0 
Incontinence, n(%) 1 (1) 33 (7) 0.04 0 
Medications 
BB, n(%) 57 (66) 392 (84) <0.001 0 
ACEi/ARB, n(%) 51 (59) 389 (83) <0.001 0 
MRA, n(%) 1 (1) 214 (46) <0.001 0 
Digoxin, n(%) 0 100 (21) <0.001 0 
Loop diuretic, n(%) 3 (3) 347 (74) <0.001 0 
Thiazide, n(%) 8 (9) 17 (4) 0.02 0 
≥5 ŵedicatioŶs, Ŷ ;%Ϳ 58 (67) 404 (87) <0.001 0 
Blood tests 
NTproBNP (ng/L) 170 
(99-278) 
1156 
(496-2463) 
<0.001 2 
Hb (g/dL) 139  
(127-147) 
131  
(118-142) 
0.007 0 
Na (mmol/L) 137  
(136-139) 
137  
(135-138) 
0.01 0 
K (mmol/L) 4.4  
(4.2-4.6) 
4.4  
(4.2-4.7) 
0.11 0 
eGFR (mL/min per 1.73 m
2 
) 77  
(64-87) 
55  
(40-73) 
<0.001 0 
Frailty screening/ assessments 
Weekly energy expenditure  
(kcal x kg
-1 
x wk
-1
)  
1080  
(735-1593) 
420  
(105-853) 
<0.001 0 
5 m walk test (>6-7sec), n(%) 10 (12) 294 (63) <0.001 0 
TUGT >10sec, n(%) 19 (22)  325 (69)  <0.001 0 
Grip strength (kg) 34  
(22-40) 
20  
(14-33) 
<0.001 0 
Frailty screening  
CFS (>4), n(%) 
AFN (frail), n(%) 
DFI (frail), n(%) 
 
3 (3) 
13 (15) 
6 (7) 
 
206 (44) 
217 (47) 
224 (48) 
 
<0.001 
<0.001 
<0.001 
0 
Frailty assessment  
Fried criteria 
 
Deficit index 
 
Edmonton frailty scale 
 
0  
(0-1) 
0.14  
(0.11-0.19) 
2 (1-3) 
 
3  
(1-4) 
0.28  
(0.20-0.38) 
5 (3-8) 
 
<0.001 
 
<0.001 
 
<0.001 
0 
HF= heart failure, HR= heart rate, BP= blood pressure, NYHA= new York heart association, HeFREF= 
heart failure with reduced ejection fraction, HeFNEF= heart failure with normal ejection fraction, 
LVEF= left ventricular ejection fraction, BMI= body mass index, MI= myocardial infarction, PVD= 
peripheral vascular disease, HTN= hypertension, CVA/TIA= cerebrovascular accident/ transient 
ischaemic attack, COPD= chronic obstructive pulmonary disease, BB= beta-blocker, ACEi= 
angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, MRA= 
mineralocorticoid receptor antagonist, NTproBNP= N-terminal pro-B-type natriuretic peptide, Hb= 
haemoglobin, Na= sodium, K= potassium, eGFR = estimated glomerular filtration rate, 5m= 5 meter, 
TUGT= timed get up and go test, CFS= clinical frailty scale, AFN= acute frailty network frailty criteria, 
DFI= Derby frailty index. 
 
Table 1b. Baseline characteristics of frail vs non-frail HF patients categorised according to different frailty assessment tools. 
 Frailty Assessment in patients with HF 
(N=467) 
Missing 
Fried criteria Deficit Index Edmonton Frail Scale 
Non-frail 
(N=223) 
Frail 
(N=244) 
p Non-frail 
(N=302) 
Frail 
(N=165) 
p Non-frail 
(N=327) 
Frail 
(N=140) 
p  
Demographics 
Age, years 72 
(64-78) 
80 
(74-84) 
<0.001 74 
(66-80) 
80 
(74-85) 
<0.001 74 
(66-80) 
80 
(75-85) 
<0.001 0 
Age≥85 years, n(%) 21(9) 60(25) <0.001 38(13) 44(27) <0.001 42(13) 39(28) <0.001 0 
Sex (male), n(%) 165(74) 148(61) 0.002 214(71) 99(60) 0.02 224(69) 89(64) 0.30 0 
HR (bpm) 70  
(61-77) 
71  
(60-82) 
0.14 70  
(60-80) 
70  
(62-82) 
0.80 70  
(60-79) 
70  
(61-83) 
0.21 0 
BP systolic (mmHg) 140  
(125-157) 
138 
 (126-166) 
0.17 140  
(125-158) 
137  
(128-167) 
0.15 141 
 (126-162) 
137  
(125-162) 
0.79 0 
BP diastolic (mmHg) 74  
(67-83) 
75  
(65-83) 
0.35 75  
(67-83) 
74  
(65-83) 
0.43 75  
(67-83) 
73  
(64-82) 
0.02 0 
NYHA, n(%) 
I/II  
III/IV 
 
205 (92) 
18 (8) 
 
159 (65) 
85 (35) 
<0.001  
262 (87) 
40 (13) 
 
102 (62) 
63 (38) 
<0.001  
283 (86) 
44 (14) 
 
81 (58) 
59 (42) 
<0.001 0 
HF phenotype, n(%) 
HeFREF 
HeFNEF 
 
153 (69) 
70 (31) 
 
138 (57) 
106 (43) 
0.007  
201 (67) 
101 (33) 
 
90 (54) 
75 (46) 
0.10  
212 (65) 
115 (35) 
 
79 (56) 
61 (44) 
0.09 0 
LVEF (%) 45 
(35-54) 
45 
(35-55) 
0.86 45 
(34-54) 
45 
(35-56) 
0.26 45 
(35-54) 
45 
(35-55) 
0.87 160 
LV impairment, n(%) 
None-mild 
Moderate-severe 
 
113 (51) 
110 (49) 
 
 
139 (57) 
105 (43) 
 
0.17  
154 (51) 
148 (49) 
 
 
98 (59) 
67 (41) 
 
0.08  
168 (51) 
159 (49) 
 
 
84 (60) 
56 (40) 
 
0.09 0 
Height (m) 1.70  
(1.64-1.76) 
1.66  
(1.59-1.74) 
<0.001 1.70  
(1.63-1.75) 
1.65  
(1.59-1.74) 
0.001 1.69 
 (1.62-1.75) 
1.65 
 (1.59-1.74) 
0.003 0 
Weight (kg) 86  
(74-102) 
79  
(66-96) 
0.006 84  
(72-99) 
78 
(66-97) 
0.05 84  
(72-99) 
78  
(64-97) 
0.003 0 
BMI (kg/m2) 29.4  
(26.0-33.3) 
28.7  
(24.4-32.8) 
0.15 29.1 
 (25.6-33.2) 
28.8 
(24.3-33.1) 
0.52 29.1 
 (25.8-33.3) 
28.6 
 (23.6-32.7) 
0.07 0 
BMI categories (kg/m2) 
<24.9 
25.0-29.9 
≥30.0 
 
44 (20) 
79 (35) 
100 (45) 
 
67 (28) 
79 (32) 
98 (40) 
0.15  
65 (22) 
110 (36) 
127 (42) 
 
46 (28) 
48 (29) 
71 (43) 
0.17  
65 (20) 
119 (36) 
143 (44) 
 
46 (33) 
39 (28) 
55 (39) 
0.009 
 
0 
Comorbidities 
Charlson score 7  
(5-9) 
9  
(8-11) 
<0.001 7  
(5-9) 
10  
(9-12) 
<0.001 8  
(6-9) 
10 
 (8-12) 
<0.001 0 
MI, n(%) 98 (44) 100 (41) 0.52 121 (40) 77 (47) 0.17 142 (43) 56 (40) 0.49 0 
PVD, n(%) 28 (13) 44 (18) 0.10 34 (11) 38 (23) 0.001 42 (13) 30 (21) 0.02 0 
HTN, n(%) 139 (62) 174 (71) 0.04 192 (64) 121 (73) 0.03 221 (68) 92 (66) 0.69 0 
CVA/TIA, n(%) 22 (10) 49 (20) 0.002 26 (9) 45 (27) <0.001 37 (11) 34 (24) <0.001 0 
Diabetes, n (%) 69 (31) 94 (39) 0.05 90 (30) 73 (44) 0.002 106 (33) 57 (41) 0.21 0 
Dementia, n(%) 4 (2) 44 (18) <0.001 8 (3) 40 (24) <0.001 5 (2) 43 (31) <0.001 0 
COPD, n(%) 47 (21) 93 (38) <0.001 73 (24) 67 (41) <0.001 78 (24) 62 (44) <0.001 0 
Depression, n(%) 28 (13) 65 (27) <0.001 42 (14) 51 (31) <0.001 48 (15) 45 (32) <0.001 0 
Anaemia, n(%) 77 (35) 141 (58) <0.001 110 (36) 108 (66) <0.001 126 (39) 92 (66) <0.001 0 
Recurrent falls, n(%) 32 (14) 141 (58) <0.001 63 (21) 110 (67) <0.001 83 (25) 90 (64) <0.001 0 
Incontinence, n(%) 8 (4) 25 (10) 0.005 11 (4) 22 (13) 0.001 13 (4) 20 (14) <0.001 0 
Medications 
BB, n(%) 201 (90) 191 (78) <0.001 263 (87) 129 (78) 0.01 280 (86) 112 (80) 0.13 0 
ACEi/ARB, n(%) 202 (91) 187 (77) <0.001 274 (91) 115 (70) <0.001 291 (89) 98 (70) <0.001 0 
MRA, n(%) 109 (49) 105 (43) 0.21 153 (51) 61 (37) 0.005 162 (50) 52 (37) 0.01 0 
Digoxin, n(%) 42 (19) 58 (24) 0.19 69 (23) 31 (19) 0.31 69 (21) 31 (22) 0.80 0 
Loop diuretic, n(%) 146 (66) 201 (82) <0.001 213 (71) 134 (81) 0.01 230 (70) 117 (84) 0.003 0 
Thiazide, n(%) 4 (2) 13 (5) 0.04 5 (2) 12 (7) 0.002 9 (3) 8 (6) 0.12 0 
≥5 medications, n (%) 176 (79) 228 (93) <0.001 247 (82) 157 (95) <0.001 269 (82) 135 (96) <0.001 0 
Blood tests 
NTproBNP (ng/L) 1020 
(436-2124) 
2465 
(1372-4143) 
<0.001 919 
(402-1899) 
1669 
(812-3426) 
<0.001 963 
(426-1919) 
2613 
(1013-4712) 
<0.001 2 
Hb (g/dL) 132 
(120-143) 
121  
(110-131) 
<0.001 135 
(123-144) 
121 
(112-134) 
<0.001 134  
(121-144) 
120  
(109-131) 
<0.001 0 
Na (mmol/L) 137  
(135-138) 
136  
(133-138) 
0.05 137 
(135-138) 
136  
(134-138) 
0.09 137 
(135-138) 
136  
(134-138) 
0.22 0 
K (mmol/L) 4.4 
(4.2-4.7) 
4.3  
(4.1-4.8) 
0.32 4.5  
(4.2-4.7) 
4.4 
(4.1-4.7) 
0.11 4.5  
(4.2-4.7) 
4.3  
(4.1-4.6) 
0.007 0 
eGFR (mL/min per 1.73 m2 ) 59  55  0.99 61  48  0.004 56  52  0.02 0 
HF= heart failure, HR= heart rate, BP= blood pressure, NYHA= new York heart association, HeFREF= heart failure with reduced ejection 
fraction, HeFNEF= heart failure with normal ejection fraction, LVEF= left ventricular ejection fraction, BMI= body mass index, MI= 
myocardial infarction, PVD= peripheral vascular disease, HTN= hypertension, CVA/TIA= cerebrovascular accident/ transient ischaemic attack, 
COPD= chronic obstructive pulmonary disease, BB= beta-blocker, ACEi= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor 
blocker, MRA= mineralocorticoid receptor antagonist, NTproBNP= N-terminal pro-B-type natriuretic peptide, Hb= haemoglobin, Na= sodium, 
K= potassium, eGFR = estimated glomerular filtration rate, 5m= 5 meter, TUGT= timed get up and go test, CFS= clinical frailty scale, AFN= 
acute frailty network frailty criteria, DFI= Derby frailty index. 
 
(37-76) (40-73) (45-76) (32-63) (41-74) (33-70) 
Frailty screening/ assessments 
Frailty screening  
CFS (>4), n(%) 
AFN (frail), n(%) 
DFI (frail), n(%) 
 
 
14 (6) 
45 (20) 
51 (23) 
 
192 (79) 
172 (70) 
173 (71) 
 
 
<0.001 
<0.001 
<0.001 
 
 
52 (17) 
88 (29) 
105 (35) 
 
 
154 (93) 
129 (78) 
119 (72) 
 
 
<0.001 
<0.001 
<0.001 
 
 
72 (22) 
102 (31) 
118 (36) 
 
 
134 (96) 
115 (82) 
106 (76) 
 
 
<0.001 
<0.001 
<0.001 
0 
Table 2. Prevalence of pre-frailty and frailty in HF vs controls according to different frailty tools. 
 
 
 
HF= heart failure, Fried= fried criteria, DI= deficit index, EFS= Edmonton frailty scale, CFS= clinical frailty scale, AFN= acute frailty network 
frailty criteria, DFI= derby frailty index.  
 PRE-FRAILTY FRAILTY 
Assessment tools Screening tools 
Fried 
1-2 
(N=184) 
DI 
middle tertile 
(N=177) 
EFS 
6-7 
(N=93) 
Fried  
≥3 
(N=250) 
DI 
upper tertile   
(N=193) 
EFS 
≥8 
(N=142) 
CFS 
>4 
(N=209) 
AFN 
Frail 
(N=230) 
DFI 
Frail 
(N=230) 
 
HF 
(N=467) 
 
Controls  
(N=87)  
P (HF vs controls) 
 
32% 
(N=148) 
  DI<0.15            DI<0.25 
     0                22% 
                                   (N=32) 
 
 
19% 
(N=90) 
 
52% 
(N=244) 
  DI=0.40-0.49            DI≥0.5 
       35%               29% 
         (N=57)                        (N=48) 
              
 
30% 
(N=140) 
 
44% 
(N=206) 
 
47% 
(N=217) 
 
48% 
(N=224) 
41% 
(N=36 ) 
   70%            100%      
   (N=21)                   (N=30) 
3% 
(N=3) 
7% 
(N=6) 
        7%                  4%      
       (N=2)                           (N=1) 
2% 
(N=2) 
3% 
(N=3) 
15% 
(N=13) 
7% 
(N=6) 
0.08 NA <0.001 <0.001 NA <0.001 <0.001 <0.001 <0.001 
Table 3. Prevalence of frailty in different subgroups of patients with CHF. 
 FRAILTY 
Assessment tools Screening tools 
Fried 
(N=250) 
DI 
(N=165) 
EFS 
(N=142) 
CFS 
(N=209) 
AFN 
(N=230) 
DFI 
(N=230) 
H
ea
rt
 
rh
yt
hm
 
 
SR 
(N=252) 
46%  
(N=116) 
32%  
(N=80) 
25%  
(N=64) 
39%  
(N=98) 
40%  
(N=100) 
43%  
(N=108) 
AF  
(N=215) 
60%  
(N=128) 
40%  
(N=85) 
35%  
(N=76) 
50%  
(N=108) 
54% 
(N=117) 
54%  
(N=116) 
P (SR vs AF) 0.004 0.02 0.02 0.02 0.001 0.02 
BM
I c
at
eg
or
ie
s 
(k
g/m
2 ) <24.9  
(N=111) 
60%  
(N=67)  
41%  
(N=46) 
41%  
(N=46) 
53% 
(N=59) 
62% 
(N=69) 
64%  
(N=71) 
25.0-29.9  
(N=158) 
50%  
(N=79) 
30% 
(N=48) 
25% 
(N=39) 
42% 
(N=66) 
45% 
(N=71) 
54%  
(N=86) 
≥30 
(N=198) 
50%  
(N=98) 
36% 
(N=71) 
28% 
(N=55) 
41% 
(N=81) 
39% 
(N=77) 
34% 
(N=67) 
P (BMI 
categories) 
0.15 0.17 0.009 0.09 <0.001 <0.001 
H
F 
ph
en
ot
yp
e HeFREF 
(N=291) 
HeFNEF 
(N=176) 
P (HeFREF vs 
HeFNEF) 
47%  
(N=138) 
31%  
(N=90) 
27%  
(N=79) 
40%  
(N=117) 
39%  
(N=114) 
42%  
(N=122) 
60% 
(N=106) 
43%  
(N=75) 
35%  
(N=61) 
51%  
(N=89) 
59%  
(N=103) 
58%  
(N=102) 
0.007 0.01 0.09 0.03 <0.001 0.001 
N
Y
H
A
 
I/II   
(N=364) 
44%  
(N=159) 
28%  
(N=102) 
22%  
(N=81) 
35%  
(N=128) 
40%  
(N=145) 
42%  
(N=154) 
III/IV  
(N=103) 
83% 
(N=85) 
61%  
(N=63) 
57%  
(N=59) 
76% 
(N=78) 
70%  
(N=72) 
68%  
(N=70) 
P ( I/II vs III/IV) <0.001 
N
Tp
ro
BN
P 
 
(n
g/L
) <1000 (N=215) 
41%  
(N=88) 
26%  
(N=56) 
22%  
(N=47) 
33%  
(N=70) 
32%  
(N=68) 
35%  
(N=76) 
1000-2000 
(N=108) 
55%  
(N=59) 
35%  
(N=38) 
30%  
(N=32) 
45%  
(N=49) 
52%  
(N=56) 
54%  
(N=58) 
>2000 
(N=144) 
67%  
(N=97) 
49%  
(N=71) 
42%  
(N=61) 
60%  
(N=87) 
65%  
(N=93) 
63%  
(N=90) 
P (NTproBNP 
categories) 
<0.001 
 Fried= fried criteria, DI= deficit index, EFS= Edmonton frailty scale, CFS= clinical frailty 
scale, AFN= acute frailty network frailty criteria, DFI= derby frailty index, SR= sinus 
rhythm, AF= atrial fibrillation, BMI= body mass index, HeFREF= heart failure with reduced 
ejection fraction, HeFNEF= heart failure with normal ejection fraction, NYHA= New York 
heart association classification, NTproBNP= N-terminal pro B type natriuretic peptide. 
 
A
ge
 (y
ea
rs)
 
<65 
(N=82) 
28%  
(N=23) 
20%  
(N=16) 
12%  
(N=10) 
22%  
(N=18) 
NA 
 
NA 
65-75 
(N=139) 
35%  
(N=49) 
23%  
(N=32) 
18%  
(N=25) 
27%  
(N=38) 
32%  
(N=44) 
9%  
(N=13) 
>75 
(N=246) 
70%  
(N=172) 
48%  
(N=117) 
43%  
(N=105) 
61%  
(N=150) 
70%  
(N=173) 
86%  
(N=211) 
P (Age categories) <0.001 
Table 4: Correlation coefficients for frailty tools 
 
 
 
 
 
 
 
 
 
 
 
 
AFN= acute frailty network frailty criteria, DFI= derby frailty index, CFS= clinical frailty 
scale, Fried = Fried criteria, EFS= Edmonton frailty scale, DI= deficit index. 
 
All p values < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
Indices Screening tools Assessment tools 
DFI AFN CFS Fried EFS 
Sc
re
en
in
g 
to
o
ls 
AFN 0.60     
CFS 0.54 0.59    
A
ss
es
sm
en
t 
to
o
ls 
Fried 0.54 0.57 0.86   
EFS 0.50 0.56 0.89 0.81  
DI 0.48 0.53 0.87 0.77 0.86 
Table 5. Agreement between frailty screening vs assessment tools 
 
 
 
CFS= clinical frailty scale, AFN= acute frailty network frailty criteria, DFI= derby frailty 
index, Fried= fried criteria, DI= deficit index, EFS= Edmonton frailty scale, K= kappa 
coefficient 
FRAILTY SCREENING TOOLS 
CFS AFN DFI 
Non-frail 
(N=261) 
Frail 
(N=206) 
Non-frail 
(N=250) 
Frail 
(N=217) 
Non-frail 
(N=243) 
Frail 
(N=224) 
A
S
S
E
S
S
M
E
N
T
 T
O
O
L
S
 
F
R
IE
D
 
Non-frail 
(N=223) 
45% 
(N=209) 
3% 
(N=14) 
38% 
(N=178) 
10% 
(N=45) 
37% 
(N=172) 
11% 
(N=51) 
Frail 
(N=244) 
11% 
(N=52) 
41% 
(N=192) 
15% 
(N=72) 
37% 
(N=172) 
15% 
(N=71) 
37% 
(N=173) 
 K=0.72 
P<0.001 
K=0.50 
P<0.001 
K=0.48 
P<0.001 
D
I 
Non-frail 
(N=302) 
54% 
(N=250) 
11% 
(N=52) 
46% 
(N=214) 
19% 
(N=88) 
42% 
(N=197) 
22% 
(N=105) 
Frail 
(N=165) 
2% 
(N=11) 
33% 
(N=154) 
8% 
(N=36) 
27% 
(N=129) 
10% 
(N=46)  
26% 
(N=119) 
 K=0.72 
P<0.001 
K=0.46 
P<0.001 
K=0.35 
P<0.001 
E
F
S
 
Non-frail 
(N=327) 
55% 
(N=255)  
15% 
(N=72) 
 48% 
(N=225) 
22% 
(N=102) 
45% 
(N=209) 
25% 
(N=118)  
Frail 
(N=140) 
1% 
(N=6) 
29% 
(N=134) 
5% 
(N=25) 
25% 
(N=115) 
7% 
(N=34) 
23% 
(N=106) 
 K=0.65 
P<0.001 
K=0.44 
P<0.001 
K=0.34 
P<0.001 
Table 6. Sensitivity, specificity and misclassification rates of different frailty tools (screening 
vs assessment vs single physical tests) in identifying frailty according to the combined index 
(the presumed gold standard for identifying frailty).  
 
 
EFS= Edmonton frailty scale, DI= deficit index, Fried= Fried criteria, DFI= derby frailty 
index, AFN= acute frailty network frailty criteria, CFS= clinical frailty scale, 5m= 5 meter, 
TUGT= timed get up and go test, PPV= positive predictive value, NPV= negative predictive 
value. 
* frail according to Fried criteria 
 
 Frailty tools 
Screening Assessment Single physical tests 
CFS 
>4 
AFN 
(Frail) 
DFI 
(Frail) 
Fried 
≥3 
EFS 
≥8 
DI 
(upper 
tercile) 
Grip 
strength* 
5m 
walk 
test* 
TUGT 
>10sec 
Sensitivity (%) 87 79 76 93 62 75 93 95 97 
Specificity (%) 89 78 73 76 98 92 58 59 55 
PPV (%) 86 72 67 73 96 88 61 62 66 
NPV (%) 90 83 81 94 74 81 92 94 96 
False positive 
(%) 
6 13 16 14 1 5 25 24 24 
False negative 
(%) 
6 9 10 3 18 12 3 2 1 
Misclassification 
rate (%) 
12 22 26 17 19 17 28 26 25 
